Reported 8 months ago
Developed by Li Hanmin on June 24, 2024, at 4:10 PM, Xin Cheng Magnesium (6934), an internationally recognized expert in nebulizer solutions, launched on the Emerging Stock Market with a focus on developing medical nebulizers. Their innovative vibrating mesh nebulization technology can nebulize high-value therapeutic drugs, both small and large molecules, including solutions, suspensions, and highly viscous drugs. Their products have obtained medical device approvals in several countries, with their second-generation nebulizer AdheResp Series featuring breath detection and automatic adjustment of nebulization output. Xin Cheng Magnesium's nebulizers have garnered attention from international pharmaceutical companies, with collaborations such as exclusive sales agreements with Abbott and assisting in developing new antibiotic nebulizer drugs. They aim to launch self-developed drug-device combination products to treat rare diseases like cystic fibrosis in the US market by 2027-2028, following the FDA's 505(b)(2) approval process.
Source: YAHOO